dulaglutide + oral antihyperglycemics

**Dulaglutide + oral antihyperglycemics** is not a single approved pharmaceutical product, but rather describes the combination therapy of **dulaglutide**, a glucagon-like peptide-1 (GLP-1) receptor agonist, with one or more **oral antihyperglycemic medications** in the management of type 2 diabetes mellitus. Dulaglutide acts by stimulating insulin secretion and suppressing glucagon in a glucose-dependent manner, as well as slowing gastric emptying, leading to improved glycemic control. Oral antihyperglycemics in this context may include classes such as biguanides (e.g., metformin), sulfonylureas, thiazolidinediones, SGLT2 inhibitors, \u03b1-glucosidase inhibitors, or glinides. This combination is used as an adjunct to diet and exercise to improve glycemic control, and clinical studies show that combination therapy improves HbA1c more than monotherapy. Dulaglutide+oral antihyperglycemics is not a fixed-dose coformulation but rather a common clinical strategy in diabetes management[1][3][5].